Hims & Hers stock jumps 14% after FDA schedules peptide compounding review Apr 17, 2026 · The FDA will convene an outside panel in July to weigh compounding eligibility for 7 peptides, a category Hims & Hers has been positioning to enter Read more »
.png?branch=production&format=jpg&width=1024)
